Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion")

× No keyword cloud information.

7 in total

1. Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.

Authors: Chris Fellner
Journal: P T Date: 2016-08

Review 2. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.

Authors: Ryota Tamura; Toshihide Tanaka; Yasuharu Akasaki; Yuichi Murayama; Kazunari Yoshida; Hikaru Sasaki
Journal: Med Oncol Date: 2019-11-11 Impact factor: 3.064

Review 3. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.

Authors: Kenneth G Liu; Sorab Gupta; Sanjay Goel
Journal: Oncotarget Date: 2017-03-07

4. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.

Authors: Ryota Tamura; Toshihide Tanaka; Kentaro Ohara; Keisuke Miyake; Yukina Morimoto; Yohei Yamamoto; Ryuichi Kanai; Yasuharu Akasaki; Yuichi Murayama; Takashi Tamiya; Kazunari Yoshida; Hikaru Sasaki
Journal: Cancer Sci Date: 2018-12-21 Impact factor: 6.716

Review 5. Immune checkpoint inhibitors in renal cell carcinoma.

Authors: Kirsty Ross; Rob J Jones
Journal: Clin Sci (Lond) Date: 2017-10-27 Impact factor: 6.124

Review 6. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors: Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal: Front Immunol Date: 2020-08-28 Impact factor: 7.561

7. Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer.

Authors: Yun Ding; Yuanyuan Fu; Wei Wei; Weibin Huang; Zhuojun Zheng; Dachuan Zhang; Jiajia He; Xiao Zheng; Qi Wang; Yingting Liu; Wendong Gu; Jingting Jiang
Journal: Transl Cancer Res Date: 2021-01 Impact factor: 1.241